ContextVision (CONTX) Hisse Özeti
Bir yazılım şirketi olan ContextVision AB (publ), Asya, Avrupa ve Amerika'da tıbbi sistemler için görüntü analizi ve görüntüleme hizmetleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 1/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
CONTX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ContextVision AB (publ) Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | NOK 3.11 |
| 52 Haftanın En Yüksek Seviyesi | NOK 4.94 |
| 52 Haftanın En Düşük Seviyesi | NOK 2.70 |
| Beta | 0.21 |
| 1 Aylık Değişim | -21.66% |
| 3 Aylık Değişim | 0.65% |
| 1 Yıllık Değişim | -36.53% |
| 3 Yıllık Değişim | -61.12% |
| 5 Yıllık Değişim | -83.43% |
| Halka arzdan bu yana değişim | -15.95% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.Anlatı Güncellemesi • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.Anlatı Güncellemesi • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.Recent updates
Anlatı Güncellemesi • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.Anlatı Güncellemesi • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.Anlatı Güncellemesi • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.Anlatı Güncellemesi • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.Anlatı Güncellemesi • Feb 24
CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.Anlatı Güncellemesi • Feb 09
CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook
Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).Anlatı Güncellemesi • Jan 25
CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).Anlatı Güncellemesi • Jan 10
CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook
Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.Anlatı Güncellemesi • Dec 25
CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.Anlatı Güncellemesi • Dec 11
CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook
Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.Anlatı Güncellemesi • Nov 27
CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside
Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.Analiz Makalesi • Nov 19
More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%
The ContextVision AB (publ) ( OB:CONTX ) share price has fared very poorly over the last month, falling by a...Anlatı Güncellemesi • Nov 12
CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance
Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.Analiz Makalesi • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...Analiz Makalesi • Sep 09
We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings
A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...Analiz Makalesi • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...Anlatı Güncellemesi • Aug 09
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).Analiz Makalesi • May 09
This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts
One thing we could say about the covering analyst on ContextVision AB (publ) ( OB:CONTX ) - they aren't optimistic...Analiz Makalesi • Mar 04
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
The market for ContextVision AB (publ)'s ( OB:CONTX ) shares didn't move much after it posted weak earnings recently...
Yeni Anlatı • Feb 26
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.Analiz Makalesi • Feb 25
Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%
ContextVision AB (publ) ( OB:CONTX ) shares have had a really impressive month, gaining 25% after a shaky period...Analiz Makalesi • Feb 15
Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not have the largest market cap around , it saw a significant share...Analiz Makalesi • Sep 02
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Shareholders appeared unconcerned with ContextVision AB (publ)'s ( OB:CONTX ) lackluster earnings report last week. Our...Analiz Makalesi • Mar 11
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
ContextVision AB (publ) ( OB:CONTX ) shares have had a horrible month, losing 26% after a relatively good period...Analiz Makalesi • Feb 22
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from ContextVision AB (publ) ( OB:CONTX ) was disappointing for shareholders. However...Analiz Makalesi • Feb 18
ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 17% to kr7.50...Analiz Makalesi • Jan 26
Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
With a price-to-earnings (or "P/E") ratio of 18.4x ContextVision AB (publ) ( OB:CONTX ) may be sending very bearish...Analiz Makalesi • Jun 22
When Should You Buy ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not be the most widely known stock at the moment, it saw a decent...Hissedar Getirileri
| CONTX | NO Healthcare Services | NO Pazar | |
|---|---|---|---|
| 7D | -6.3% | 2.3% | -0.9% |
| 1Y | -36.5% | -11.8% | 17.7% |
Getiri vs. Endüstri: CONTX geçen yıl % -11.8 oranında getiri sağlayan Norwegian Healthcare Services sektörünün gerisinde kaldı.
Getiri vs Piyasa: CONTX geçen yıl % 17.7 oranında getiri sağlayan Norwegian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| CONTX volatility | |
|---|---|
| CONTX Average Weekly Movement | 7.0% |
| Healthcare Services Industry Average Movement | 6.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in NO Market | 11.6% |
| 10% least volatile stocks in NO Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: CONTX son 3 ayda Norwegian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: CONTX 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1989 | 43 | Gerald Potzsch | www.contextvision.se |
Bir yazılım şirketi olan ContextVision AB (publ), Asya, Avrupa ve Amerika'da tıbbi sistemler için görüntü analizi ve görüntüleme hizmetleri sunmaktadır. Ultrason için görüntü kalitesi çözümleri ve 2D görüntü iyileştirme ürünü Rivent; premium 2D görüntü iyileştirme ürünü Rivent Plus; 3D ultrason görüntü kalitesini iyileştirme çözümü Rivent 3D ve radyoloji, kardiyoloji, kadın sağlığı, veterinerlik ve bakım noktası uygulamaları dahil olmak üzere çeşitli alanlarda teşhis için el cihazları için 2D görüntü iyileştirme ürünü Rivent Mobile'dan oluşan Rivent platformu sunmaktadır. Şirket ayrıca, statik uygulamalar için Altumira ve dinamik uygulamalar için Altumira Plus gibi görüntü kalitesini artırırken radyasyon dozunun azaltılmasını sağlayarak radyografiyi iyileştiren ve saçılma düzeltme özelliğine sahip Altumira platformunu da sunmaktadır.
ContextVision AB (publ) Temel Bilgiler Özeti
| CONTX temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | NOK 267.49m |
| Kazançlar(TTM) | NOK 4.74m |
| Gelir(TTM) | NOK 113.97m |
48.9x
F/K Oranı2.0x
P/S OranıCONTX aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| CONTX gelir tablosu (TTM) | |
|---|---|
| Gelir | SEK 113.49m |
| Gelir Maliyeti | SEK 64.90m |
| Brüt Kâr | SEK 48.59m |
| Diğer Giderler | SEK 43.88m |
| Kazançlar | SEK 4.72m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 27, 2026
| Hisse başına kazanç (EPS) | 0.063 |
| Brüt Marj | 42.82% |
| Net Kâr Marjı | 4.16% |
| Borç/Özkaynak Oranı | 0% |
CONTX uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/09 21:34 |
| Gün Sonu Hisse Fiyatı | 2026/06/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ContextVision AB (publ) 3 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Juste Subataviciute | Norne Securities AS |
| Christian Lee | Pareto Securities |
| Klas Palin | Redeye |